Cresco Labs (FRA:6CQ) Return-on-Tangible-Equity: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6CQ Cresco Labs Inc FRA:6CQ
43 GF Score
Price €0.63
GF Value €0.88
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Cresco Labs Return-on-Tangible-Equity?

Cresco Labs FRA:6CQ -0.32% 43 Return-on-Tangible-Equity is 0.00% as of Mar. 2026. GuruFocus rates FRA:6CQ with a GF Score™ of 43/100 and a GF Value™ of €0.88 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 901 Drug Manufacturers companies, Cresco Labs ranks worse than 110987.68% on this metric.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Cresco Labs's annualized net income for the quarter that ended in Mar. 2026 was €-45.2 Mil. Cresco Labs's average shareholder tangible equity for the quarter that ended in Mar. 2026 was €-130.9 Mil. Therefore, Cresco Labs's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was N/A%.

The historical rank and industry rank for Cresco Labs's Return-on-Tangible-Equity or its related term are showing as below:

FRA:6CQ's Return-on-Tangible-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.9
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Cresco Labs  (FRA:6CQ) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Cresco Labs Return-on-Tangible-Equity Related Terms


Cresco Labs Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for Cresco Labs's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cresco Labs Return-on-Tangible-Equity Chart

Cresco Labs Annual Data
Trend Jan16 Jan17 Jan18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cresco Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:6CQ vs ZTS, UTHR: Return-on-Tangible-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cresco Labs's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cresco Labs Return-on-Tangible-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cresco Labs's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Cresco Labs's Return-on-Tangible-Equity falls into.


FRA:6CQ
43GF Score
Cresco Labs Inc FRA:6CQ
Return-on-Tangible-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cresco Labs Return-on-Tangible-Equity Calculation

Cresco Labs's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-115.638/( (-98.005+-122.179 )/ 2 )
=-115.638/-110.092
=N/A %

Cresco Labs's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-45.228/( (-122.179+-139.666)/ 2 )
=-45.228/-130.9225
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2026) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of 0.00% mean?
Cresco Labs (FRA:6CQ) has a Return-on-Tangible-Equity of 0.00% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Cresco Labs and its competitors. According to the industry distribution chart, Cresco Labs ranks #999999 out of 901 companies in the Drug Manufacturers industry.
Is Cresco Labs' Return-on-Tangible-Equity too high?
Cresco Labs' current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, Cresco Labs ranks #999999 out of 901 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cresco Labs has a GF Score™ of 43/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cresco Labs' Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cresco Labs ranks #999999 out of 901 companies for Return-on-Tangible-Equity. This places Cresco Labs in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Cresco Labs and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cresco Labs's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cresco Labs stock overvalued right now?
Based on GuruFocus' analysis, Cresco Labs (FRA:6CQ) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.88, compared to a current price of €0.63 — trading 29% below its estimated fair value. The current Return-on-Tangible-Equity is 0.00%. Cresco Labs' overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Cresco Labs (FRA:6CQ), the current Return-on-Tangible-Equity is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cresco Labs (FRA:6CQ) Overvalued in 2026?

Based on GuruFocus' analysis, Cresco Labs stock appears to be undervalued. The current stock price of €0.63 is trading 29% below its estimated GF Value™ of €0.88. GuruFocus considers Cresco Labs to be Modestly Undervalued.

Key valuation signals for FRA:6CQ:

  • Return-on-Tangible-Equity: 0.00%
  • GF Value™: €0.88 vs. price of €0.63 (29% below fair value)
  • GF Score™: 43/100 with 5 warning signs

No single metric tells the full story. See the FRA:6CQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cresco Labs Business Description

Address 600 W. Fulton Street, Suite 800, Chicago, IL, USA, 60661
Cresco Labs Inc is a vertically-integrated multi-state cannabis operator in the United States licensed to cultivate, manufacture, and sell retail and medical cannabis products through Sunnyside, Cresco Lab's national dispensary brand, and others. The company operates in one segment: the cultivation, manufacturing, distribution, and sale of cannabis. The company's brand includes: Cresco, High Supply, FloraCal Farms, Good News, Wonder Wellness Co., Mindy's, and Remedi.
43GF Score

Get the complete analysis for FRA:6CQ

Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.63
Price
€0.88
GF Value